| Identification | Back Directory | [Name]
Benzamide, N-(2-aminophenyl)-4-[[2-chloro-6-[(4-methylphenyl)amino]-9H-purin-9-yl]methyl]- | [CAS]
2418559-01-8 | [Synonyms]
HDAC1/2 and CDK2-IN-1
Benzamide, N-(2-aminophenyl)-4-[[2-chloro-6-[(4-methylphenyl)amino]-9H-purin-9-yl]methyl]- | [Molecular Formula]
C26H22ClN7O | [MOL File]
2418559-01-8.mol | [Molecular Weight]
483.95 |
| Hazard Information | Back Directory | [Uses]
HDAC1/2 and CDK2-IN-1 (compound 14d) is a potent HDAC1, HDAC2 and CDK2 dual inhibitor, with IC50 values of 70.7, 23.1 and 0.80 μM, respectively. HDAC1/2 and CDK2-IN-1 can block the cell cycle and induce apoptosis. HDAC1/2 and CDK2-IN-1 exhibits desirable in vivo antitumor activity[1]. | [in vivo]
HDAC1/2 and CDK2-IN-1 (BALB/c nude mice, 0-100 mg/kg, IP, once daily for 21 days) significantly inhibits the tumor growth[1].
HDAC1/2 and CDK2-IN-1 (compound 14d) (ICR mice; 4 mg/kg, IV; 20 mg/kg, IP) exhibits desirable pharmacokinetic properties[1].
Pharmacokinetic Parameters of HDAC1/2 and CDK2-IN-1 in male ICR mice[1].
| Dose (mg/kg) | 4 | 20 | | Administration | IV | IP | | T1/2 (h) | 1.48 | 2.84 | | Tmax (h) | | 2 | | Cmax (ng/mL) | | 1360 | | AUC0-t (ng/mL*h) | 2850 | 7240 | | MRT0-t (h) | 0.563 | 4.54 | | CL (mL/(min/kg)) | 23.3 | | | F (%) | | 50.8 |
| Animal Model: | Male ICR mice (n = 9)[1] | | Dosage: | 4 mg/kg (IV), 20 mg/kg (IP) | | Administration: | IV, IP, once (Pharmacokinetic Analysis) | | Result: | Exhibited desirable pharmacokinetic properties. |
| Animal Model: | BALB/c nude mice (5-6 weeks, HCT116 xenograft model)[1] | | Dosage: | 0, 25, 50 and 100 mg/kg | | Administration: | IP, once daily for 21 days | | Result: | Significantly inhibited the tumor growth, the tumor growth inhibitions were 28%, 40% and 44% at doses of 25, 50 and 100 mg/kg, respectively. |
| [IC 50]
HDAC1: 70.7 nM (IC50); HDAC2: 23.1 nM (IC50); CDK2: 0.80 nM (IC50) | [References]
[1] Yun F, Cheng C, Ullah S, Yuan Q. Design, synthesis and biological evaluation of novel histone deacetylase1/2 (HDAC1/2) and cyclin-dependent Kinase2 (CDK2) dual inhibitors against malignant cancer. Eur J Med Chem. 2020;198:112322. DOI:10.1016/j.ejmech.2020.112322 |
|
|